All In Biotech

Drug Trial Radar · NCT04145440

Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN)

Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

31

Actual

Start

Oct 15, 2019

Primary completion

Jan 19, 2022

Study completion Aug 2, 2022

Sponsor

Lead sponsor
HI-Bio, A Biogen CompanyIndustry
Sponsor type
Industry
First posted
Oct 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)

Conditions

  • Glomerulonephritis, Membranous
  • antiPLA2R Positive

Interventions

  • MOR202Drug

    Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: Week 1 to Week 24
  2. Percentage of Participants With Adverse EventsTime frame: Week 1 to Week 24

Locations

45 sites in 9 countries. Site status is shown where the registry gives one.

  • North America Research Institute

    Azusa, California

  • UCSF Medical Center

    San Francisco, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • University of Miami Division of Nephrology & Hypertension

    Miami, Florida

  • GA Nephrology Associates

    Lawrenceville, Georgia

  • Northwest Louisiana Nephrology Research

    Shreveport, Louisiana

  • Kidney Care and Transplant Services of New England, PC

    Springfield, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • MedResearch, Inc

    El Paso, Texas

  • Texas Research Institute

    Fort Worth, Texas

  • Western Health

    Melbourne, Australia

  • St. George Hospital

    Sydney, New South Wales, Australia

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia

  • O.L.V. Ziekenhuis

    Aalst, Belgium

  • C.H.U. Brugmann - Site Victor Horta

    Brussels, Belgium

  • Universitair Ziekenhuis Brussels

    Brussels, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • UZ Leuven

    Leuven, Belgium

  • CHU de Liège

    Liège, Belgium

  • Groupe Hospitalier Pellegrin - Hôpital Pellegrin

    Bordeaux, France

  • CHU de Grenoble - Hôpital Albert Michallon

    Grenoble, France

  • Hopital Claude Huriez -CHU Lille

    Lille, France

  • Hopital Tenon Service de nephrologie

    Paris, France

  • CHU Saint Etienne - Hôpital Nord

    Saint-Priest-en-Jarez, France

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Italy

  • Ospedale San Raffaele

    Milan, Italy

  • Ospedale Borgo Roma

    Verona, Italy

  • Radboud UMC Niimegen Nephrology

    Nijmegen, Netherlands

  • SPZOZ Centralny Szpital Kliniczny UM w Lodzi

    Lodz, Poland

  • Centrum Zdrowia MDM

    Warsaw, Poland

  • Miedzyleski Szpital Specjalistyczny

    Warsaw, Poland

  • Chungnam National University Hospital

    Daejeon, South Korea

  • Hallym University Kangdong Sacred Heart Hospital

    Seoul, South Korea

  • Gangnam Severance Hospital

    Seoul, South Korea

  • The Catholic University of Korea

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Spain

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.